EKF Diagnostics, the global in vitro diagnostics company, announces that in a newly published paper its Quo-Test® point-of-care (POC) hemoglobin HbA1c analyzer has again been confirmed to meet ...

EKF Diagnostics has announced that in a newly published paper [1] its Quo-Test® point-of-care (POC) hemoglobin A1c (HbA1c) analyzer has again been confirmed to meet International Federation of ...

EKF Diagnostics, the global in vitro diagnostics business, announces today that the Quo-Test, its glycated haemoglobin (HbA1c) analyser for near-patient monitoring of diabetes will be on show at Heart ...

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use ...

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, announces that its wholly owned subsidiary, Quotient Diagnostics Limited ("Quotient"), has received approval ...